Search This Blog

Monday, February 11, 2019

Stifel Resumes FibroGen (FGEN) at Buy

Stifel analyst Adam Walsh resumes coverage on FibroGen (NASDAQ: FGEN) with a Buy rating and a price target of $71.

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)